Glaucoma Drug Clinical Trials Offer Promising Results

June 30, 2022

The results of Phase 2 clinical trials for glaucoma drug QLS-101 have demonstrated a favorable safety and tolerability profile, according to a news release by Qlaris Bio, which licensed the drug in 2019. A positive efficacy signal was also reported. Read the full story on the University of Minnesota College of Pharmacy website.

Categories: Health Sciences News